Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Purpose: Lutetium labelled prostate-specific membrane antigen radioligand therapy (Lu-PSMA RLT) has shown pleasing early results in management of high-volume metastatic castration resistant prostate cancer (mCRPC), but its role in the early treatment of men with only lymph node metastasis (LNM) is u...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: William John Yaxley, Rhiannon McBean, David Wong, David Grimes, Paul Vasey, Mark Frydenberg, John William Yaxley
Formato: article
Lenguaje:EN
Publicado: Korean Urological Association 2021
Materias:
lutetium-177
lymphatic metastasis
prostate cancer
psma-617
Diseases of the genitourinary system. Urology
RC870-923
Acceso en línea:https://doaj.org/article/f09385922af24e11a3b719c3f5dde7df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares